Edgewise Therapeutics Ownership
| EWTX Stock | USD 23.61 0.21 0.88% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 93.8 M | Current Value 92.4 M | Avarage Shares Outstanding 53.4 M | Quarterly Volatility 26.8 M |
Edgewise |
Edgewise Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Edgewise Therapeutics was currently reported as 4.84. The company recorded a loss per share of 1.45. Edgewise Therapeutics had not issued any dividends in recent years. Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Edgewise Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people. To learn more about Edgewise Therapeutics call Kevin Koch at 720 262 7002 or check out https://www.edgewisetx.com.Besides selling stocks to institutional investors, Edgewise Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Edgewise Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Edgewise Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Edgewise Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Edgewise Therapeutics Insider Trades History
Less than 1% of Edgewise Therapeutics are currently held by insiders. Unlike Edgewise Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Edgewise Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Edgewise Therapeutics' insider trades
Edgewise Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edgewise Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edgewise Therapeutics backward and forwards among themselves. Edgewise Therapeutics' institutional investor refers to the entity that pools money to purchase Edgewise Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deerfield Management Co | 2024-12-31 | 2.1 M | State Street Corp | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Driehaus Capital Management Llc | 2024-12-31 | 1.5 M | Bellevue Group Ag | 2024-12-31 | 1.4 M | Viking Global Investors Lp | 2024-12-31 | 1.2 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 1.1 M | Artisan Partners Limited Partnership | 2024-12-31 | 1.1 M | New Leaf Venture Partners, L.l.c. | 2024-12-31 | 1 M | Orbimed Advisors, Llc | 2024-12-31 | 15 M | Ra Capital Management, Llc | 2024-12-31 | 8.9 M |
Edgewise Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edgewise Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edgewise Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edgewise Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edgewise Therapeutics Outstanding Bonds
Edgewise Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edgewise Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edgewise bonds can be classified according to their maturity, which is the date when Edgewise Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US28035QAB86 Corp BondUS28035QAB86 | View | |
| Edgewell 55 percent Corp BondUS28035QAA04 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Edgewise Therapeutics Corporate Filings
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 21st of February 2025 Other Reports | ViewVerify | |
F3 | 23rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.